Diasorin S.p.a. · MIL:DIA
Diasorin — FY2024 Earnings Presentation
18 slides from Diasorin's earnings presentation, Mar 14, 2025
Slide 1: FY 2024 Results
FY 2024 RESULTS March 14, 2025
Slide 2: Disclaimer
DISCLAIMER In General. This disclaimer applies to this presentation and any oral No distribution of this Presentation. This Presentation is being furnished to you comments of any person presenting it. This document, taken together with solely for your information and may not be reproduced, in whole
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias
Slide 4: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 5: Financial Highlights
FINANCIAL HIGHLIGHTS Change Change Data in €/mln Q4 2024 FY 2024 @ current @ CER @ current @ CER Revenues 309 +2% +2% 1,185 +3% +3% Immunodiagnostics ex-COVID 201 +6% +6% 785 +9% +9% Molecular Diagnostics ex-COVID 57 +1% +1% 204 +3% +3% Licensed Technologies1 45 +5% +4% 171 +2% +2% COVID 6 -54% -54%
Slide 6: FY 2024 Key Facts
FY 2024 KEY FACTS PRODUCT & BUSINESS DEVELOPMENT IMMUNODIAGNOSTICS • LIAISON® LymeDetect® submitted to the U.S. FDA • LIAISON® Streptococcus pneumoniae Ag launched in all countries accepting the CE Mark • Advancement of the development of the new immunodiagnostic platform LIAISON® XL 2.0 MOLECULAR D
Slide 7: Managerial Outlook on Q4 and FY 2024 Revenues
MANAGERIAL OUTLOOK ON Q4 AND FY 2024 REVENUES Q4 2024 Group revenues (data in €/mln) FY 2024 Group revenues1 (data in €/mln) Data @CUR Data @CER Data @CUR Data @CER +2% +2% +3% +3% 302 309 302 309 1,185 1,188 6 1,148 1,148 13 6 13 26 45 45 26 59 43 43 59 171 171 COVID sales 168 168 57 56 57 204 204
Slide 8: Q4 and FY 2024 Revenues by Geography
Q4 AND FY 2024 REVENUES BY GEOGRAPHY Q4 2023 Q4 2024 Rest of the World Rest of the World 17% 15% North America North America Direct Direct 49% 50% Europe Direct Europe Direct 35% 34% FY 2023 FY 2024 Rest of the World Rest of the World 17% 15% North America North America Direct Direct 49% 50% Europe
Slide 9: Q4 and FY 2024 Profitability Profile
Q4 AND FY 2024 PROFITABILITY PROFILE (data in €/mln @ current exchange rates) 32% 33% 302 309 97 102 Net Revenues FY 2024 Adjusted2 EBITDA is better than last year by €19m or 5%. Adjusted EBITDA Margin in the quarter recorded an improvement Adjusted2 EBITDA Q4 2023 Q4 2024 vs. Q4 2023, whereas in FY
Slide 10: FY 2025 Company Guidance
FY 2025 COMPANY GUIDANCE
Slide 11: Company FY 2025 Guidance
COMPANY FY 2025 GUIDANCE FY 2025 COMPANY GUIDANCE (@CER 2024) Ex-COVID revenues: approx +8%, approx. +7% including COVID revenues (equal to ~ 20 €/mln) Adjusted2 EBITDA Margin: ~ 34% 2 With reference to the Adjusted EBITDA please refer to the table included in the financial schemes section of this p
Slide 12: Financial Schemes
FINANCIAL SCHEMES
Slide 13: Income Statement
INCOME STATEMENT FY Change Amounts in million of euros 2023 2024 amount % Net Revenues 1,148 1,185 +37 +3% Cost of sales (407) (404) +3 -1% Gross profit 741 782 +41 +5% 65% 66% +139 bps Sales and marketing expenses (286) (288) -2 +1% Research and development costs (91) (92) -1 +1% General and admini
Slide 14: Balance Sheet
BALANCE SHEET Amounts in million of euros 12/31/2023 12/31/2024 Change Goodwill and intangibles assets 1,925 2,028 +104 Property, plant and equipment 256 271 +15 Other non-current assets 35 34 -0 Net working capital 369 346 -22 Other non-current liabilities (270) (264) +7 Net Invested Capital 2,314
Slide 15: Cash Flow Statement
CASH FLOW STATEMENT FY Amounts in million of euros 2023 2024 Cash and cash equivalents at the beginning of the period 242 280 Cash provided by operating activities 312 359 Cash provided/(used) in investing activities (29) (50) Cash provided/(used) in financing activities (244) (245) Net change in ca
Slide 16: FY 2024 Reconciliation to Consolidated Financial Statements
FY 2024 RECONCILIATION TO CONSOLIDATED FINANCIAL STATEMENTS Amounts in millions of Euro Gross profit EBITDA EBIT Net result IFRS Financial Statements Measures 782 387 258 187 % on Revenues 66% 33% 22% 16% Adjustments “One-off” costs related to the integration and restructuring of Luminex - 6 6 6 Dep
Slide 17: FY 2023 Reconciliation to Consolidated Financial Statements
FY 2023 RECONCILIATION TO CONSOLIDATED FINANCIAL STATEMENTS Amounts in millions of Euro Gross profit EBITDA EBIT Net result IFRS Financial Statements Measures 741 353 216 159 % on Revenues 65% 31% 19% 14% Adjustments “One-off” costs related to the integration and restructuring of Luminex 1 8 8 8 Dep
Slide 18: Slide 18